Expanding possibilities for those
living with CNS conditions.
robust, late-stage neuroscience pipeline
Sunosi
AXS-05
Alzheimer’s Disease Agitation: Breakthrough Therapy Designation
Smoking Cessation
AXS-07
Migraine
AXS-12
Narcolepsy: Orphan Therapy Designation
AXS-14
Fibromyalgia
Abbreviations: MOA = Mechanism of Action; NMDA = N-Methyl-D-aspartate; COX-2 = Cyclooxygenase-2; 5-HT = 5-Hydroxytryptamine; NE = Norepinephrine
The products and/or investigational product candidates listed on this page are not approved by the FDA or have not been approved for the above-referenced indications, and the safety and effectiveness of such has not been established.
Expanded Access PolicyYou will now be sent to a website that is not controlled or owned by Axsome Therapeutics, Inc. Axsome Therapeutics, Inc. is not responsible or liable for the website you are about to go to, which may not be appropriate for everyone.